Platelet reactivity and thrombogenicity in postmenopausal women
Authors:
- 1 January 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Menopause
- Vol. 20 (1) , 57-63
Abstract
Objective Age-adjusted incidence of cardiovascular disease, including myocardial infarction, is significantly lower in premenopausal women than in men, which is thought to be caused by the cardioprotective effects of estrogen. However, there is a consistent increase in the incidence of coronary artery disease in postmenopausal women in comparison with premenopausal women. The protective benefit of hormone therapy has not been observed in postmenopausal women. It is unknown whether measures of platelet reactivity and clot strength contribute to the disproportionate incidence of cardiovascular disease between premenopausal and postmenopausal women. Methods Fifty healthy volunteers, including 25 premenopausal women and 25 postmenopausal women, aged between 40 and 65 years were enrolled. Total estradiol and follicle-stimulating hormone levels were measured for confirmation of menopausal state and comparison testing. Platelet reactivity was assessed using light transmission aggregometry and P-selectin, and glycoprotein IIb/IIIa receptor expression was assessed using flow cytometry. Thrombelastography was used to measure clot strength, clotting time, and fibrinogen activity. Serum cholesterol, C-reactive protein, complete blood count, and comprehensive metabolic panel were also measured. Results Platelet reactivity did not differ among menopausal states or hormone levels. Clotting time was increased in postmenopausal women (6.6 ± 2.0 vs 7.8 ± 1.2 min, P = 0.013) and significantly correlated with estradiol levels (r = 0.68, P < 0.001). A significantly higher low-density lipoprotein cholesterol level was observed in postmenopausal women (P = 0.05). Mean C-reactive protein levels were numerically higher in the postmenopausal group. Conclusions The thrombotic risk profile between premenopausal and postmenopausal women is similar. However, improved management of cholesterol may be of clinical benefit. Large-scale studies are required to validate these findings.Keywords
This publication has 40 references indexed in Scilit:
- Timing and Duration of Menopausal Hormone Treatment May Affect Cardiovascular OutcomesThe American Journal of Medicine, 2011
- Oral postmenopausal hormone therapy, C-reactive protein, and cardiovascular outcomesMenopause, 2011
- Effects of the Transition from Premenopause to Postmenopause on Lipids and Lipoproteins: Quantification and Related ParametersThe Korean Journal of Internal Medicine, 2011
- Serum lipids, blood pressure and body weight around the age of the menopauseEuropean Journal of Preventive Cardiology, 2008
- Effect of menopause on platelet activation markers determined by flow cytometryAmerican Journal of Hematology, 2005
- Ethnic variations in acute coronary syndromesHeart, 2004
- Gender differences in recurrent coronary events. The FINMONICA MI registerEuropean Heart Journal, 2001
- The Estrogen Receptor Is Present in Human MegakaryocytesAnnals of the New York Academy of Sciences, 1994
- Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham populationAmerican Heart Journal, 1986
- The Degree of Coronary Atherosclerosis in Bilaterally Oophorectomized WomenCirculation, 1953